Eli Lilly Projects Revenue Surge to $94.9B by 2027 with Oral GLP-1 Boost
JNJ•Eli Lilly stock has climbed 25% over the past year following revenue growth from $28.5B in 2022 to $65.1B. Analysts project $81.7B in 2026 revenue and $94.9B by 2027, with Orforglipron sales of $1.7B next year highlighting growth potential.
1. Stock Performance and Valuation
Eli Lilly shares returned 35% in 2022, 60% in 2023 and 25% over the past year. Shares trade at roughly 39x trailing earnings of $24.21, indicating elevated valuation against historical benchmarks.
2. Revenue Growth and Forecasts
Eli Lilly's revenue rose from $28.5B in 2022 to $65.1B last twelve months, with analysts projecting $81.7B in 2026 and $94.9B by 2027, representing a 45% increase over two years.
3. Orforglipron Launch and Impact
The oral GLP-1 Orforglipron, priced at $25 per month for insured patients and up to $349 for self-pay, launches in July 2026. With an estimated 100M U.S. obesity population, Orforglipron could generate $1.7B in 2026 and peak at $35B in annual sales.
4. Path to $2,000 Share Price
Based on projected revenues of $94.9B, sustained earnings growth and valuation multiples near 27x estimated 2026 earnings, Eli Lilly could reach a $2,000 share price in the coming years.
